Use of Diuretics in Maintenance Hemodialysis Patients Undergoing Bioimpedance-guided Fluid Management

Overview

Background.The objective of the present study is to verify whether using diuretics will improve either blood pressure or fluid overload in maintenance hemodialysis patients with residual diuresis kidney function.

Full Title of Study: “Use of Diuretics in Maintenance Hemodialysis Patients With Residual Renal Function Undergoing Bioimpedance-guided Fluid Management”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Primary Purpose: Treatment
  • Masking: None (Open Label)
• Study Primary Completion Date: November 2020

Detailed Description

Methods.46 maintenance hemodialysis patients will be given three stages of diuretic intervention: 100mg furosemide every day for 1 month, 200mg furosemide every day for 1 month, and 100mg furosemide combined with 25mg hydrochlorothiazide every day for 1 month. The 24-hour urine volume, 24-hour urine sodium, 24-hour urine potassium, blood pressure, OH(overhydration) and dry weight will be collected. OH will be measured by bioelectrical impedance.

Interventions

• Drug: Furosemid hydrochlorothiazide
  • furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;

Arms, Groups and Cohorts

• Experimental: diuretics

Clinical Trial Outcome Measures

Primary Measures

• urine volume increasing after diuretic use in maintenance hemodialysis patients with residual renal function
  • Time Frame: up to 16 months

Participating in This Clinical Trial

Inclusion Criteria

• maintenance hemodialysis patient – unrine volume more than 100ml. Exclusion Criteria:

• myocardial infarction; – unrine volume less than 100ml.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

• Lead Sponsor
  • Capital Medical University
• Provider of Information About this Clinical Study
  • Principal Investigator: Dongliang Zhang, MD, professor – Peking University International Hospital
• Overall Contact(s)
  • Yunfei Ding, Master, 13521586952, dingyunfei@pkuih.edu.cn